Kepos Capital’s Fate Therapeutics FATE Stock Holding History

Kepos Capital’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-46,000	Closed	-$749K	–	365
2018 Q3	$749K	Hold	46,000	–	–	0.04%	255
2018 Q2	$522K	Buy	+46,000	New	+$507K	0.03%	274

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kepos Capital's FATE Position: Q4 2018 in Review

Kepos Capital sold out of Fate Therapeutics (FATE) in Q4 2018, closing a stake of 46,000 shares — an estimated $749K sold.

Kepos Capital first reported a position in FATE in Q2 2018 and held it in 2 quarters. The position peaked at $749K in Q3 2018. 122 funds tracked by Wall St. Rank hold FATE as of Q4 2018.

Kepos Capital reported no remaining Fate Therapeutics position as of Q4 2018 after selling out during the quarter.
Kepos Capital sold 46,000 Fate Therapeutics shares in Q4 2018, an estimated $749K.
Kepos Capital first reported a position in Fate Therapeutics in Q2 2018 and held it in 2 quarters.
Kepos Capital's Fate Therapeutics position peaked at $749K in Q3 2018.
122 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2018.

Based on Kepos Capital's 13F filing for Q4 2018, filed 13 Feb 2019.